Connection

Charles Smith to Lysophospholipids

This is a "connection" page, showing publications Charles Smith has written about Lysophospholipids.
Connection Strength

0.319
  1. Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. Sci Signal. 2015 Jun 16; 8(381):ra58.
    View in: PubMed
    Score: 0.114
  2. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011 Mar 01; 11(5):524-34.
    View in: PubMed
    Score: 0.085
  3. Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. 2015; 7(20):2611-9.
    View in: PubMed
    Score: 0.029
  4. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther. 2014 Jan; 13(1):154-64.
    View in: PubMed
    Score: 0.025
  5. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012; 7(7):e41834.
    View in: PubMed
    Score: 0.023
  6. Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. J Hepatol. 2012 Jan; 56(1):137-45.
    View in: PubMed
    Score: 0.022
  7. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis. 2010 Oct; 31(10):1787-93.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.